Sing L. George's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,962 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,962 | 1,962 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 155 | 31,007 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.01 per share. | 30 Dec 2025 | 9,212 | 37,040 (0%) | 0% | 520.0 | 4,790,332 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 9,212 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 774.03 per share. | 30 Dec 2025 | 6,188 | 30,852 (0%) | 0% | 774.0 | 4,789,698 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 31 Dec 2024 | 3,338 | 29,610 (0%) | 0% | 413.3 | 1,379,696 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 3,338 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 708.19 per share. | 31 Dec 2024 | 1,948 | 27,662 (0%) | 0% | 708.2 | 1,379,554 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 166 | 27,828 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | George L. Sing | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Sep 2024 | 1,200 | 26,272 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 03 May 2024 | 2,000 | 28,349 (0%) | 0% | 413.3 | 826,660 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 2,000 | 3,338 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 942.53 per share. | 03 May 2024 | 877 | 27,472 (0%) | 0% | 942.5 | 826,599 | Common Stock |
| Regeneron Pharma | L. Sing George | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,000 | 5,338 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | L. George Sing | Director | Sale of securities on an exchange or to another person at price $ 995.00 per share. | 26 Feb 2024 | 500 | 26,349 (0%) | 0% | 995 | 497,500 | Common Stock |
| Regeneron Pharma | George Sing L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 26 Feb 2024 | 500 | 26,849 (0%) | 0% | 413.3 | 206,665 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 26 Feb 2024 | 500 | 26,849 (0%) | 0% | 413.3 | 206,665 | Common Stock |
| Regeneron Pharma | Sing L. George | Director | Sale of securities on an exchange or to another person at price $ 990.00 per share. | 26 Feb 2024 | 500 | 26,349 (0%) | 0% | 990 | 495,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 3,000 | 6,838 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 970.00 per share. | 22 Feb 2024 | 1,000 | 26,349 (0%) | 0% | 970 | 970,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 965.00 per share. | 22 Feb 2024 | 1,000 | 26,349 (0%) | 0% | 965 | 965,000 | Common Stock |
| Regeneron Pharma | Sing L. George | Director | Sale of securities on an exchange or to another person at price $ 960.00 per share. | 22 Feb 2024 | 1,000 | 26,349 (0%) | 0% | 960 | 960,000 | Common Stock |
| Regeneron Pharma | L. George Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 22 Feb 2024 | 1,000 | 27,349 (0%) | 0% | 413.3 | 413,330 | Common Stock |
| Regeneron Pharma | Sing L. George | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 22 Feb 2024 | 1,000 | 27,349 (0%) | 0% | 413.3 | 413,330 | Common Stock |
| Regeneron Pharma | George Sing L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 22 Feb 2024 | 1,000 | 27,349 (0%) | 0% | 413.3 | 413,330 | Common Stock |
| Regeneron Pharma | L. George Sing | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 22 Feb 2024 | 500 | 26,849 (0%) | 0% | 413.3 | 206,665 | Common Stock |
| Regeneron Pharma | George Sing L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 500 | 6,338 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Sing L. George | Director | Sale of securities on an exchange or to another person at price $ 985.00 per share. | 22 Feb 2024 | 500 | 26,349 (0%) | 0% | 985 | 492,500 | Common Stock |
| Regeneron Pharma | George Sing L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 08 Feb 2024 | 500 | 26,849 (0%) | 0% | 413.3 | 206,665 | Common Stock |
| Regeneron Pharma | L. Sing George | Director | Sale of securities on an exchange or to another person at price $ 945.00 per share. | 08 Feb 2024 | 500 | 26,349 (0%) | 0% | 945 | 472,500 | Common Stock |
| Regeneron Pharma | Sing George L. | Director | Sale of securities on an exchange or to another person at price $ 955.00 per share. | 08 Feb 2024 | 500 | 26,349 (0%) | 0% | 955 | 477,500 | Common Stock |
| Regeneron Pharma | Sing George L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 500 | 9,838 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Sing George L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 500 | 10,338 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George Sing L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 08 Feb 2024 | 500 | 26,849 (0%) | 0% | 413.3 | 206,665 | Common Stock |
| Regeneron Pharma | L. Sing George | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Sing George L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 26,349 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,929 | 1,929 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 165 | 26,214 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 621.00 per share. | 25 Feb 2022 | 2,000 | 28,049 (0%) | 0% | 621 | 1,242,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 617.00 per share. | 25 Feb 2022 | 1,000 | 26,049 (0%) | 0% | 617 | 617,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 614.00 per share. | 25 Feb 2022 | 1,000 | 27,049 (0%) | 0% | 614 | 614,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,707 | 2,707 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | George L. Sing | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 191 | 30,049 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 660.00 per share. | 19 Nov 2021 | 1,000 | 29,858 (0%) | 0% | 660 | 660,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 655.00 per share. | 19 Nov 2021 | 1,000 | 30,858 (0%) | 0% | 655 | 655,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 655.00 per share. | 19 Nov 2021 | 1,000 | 31,858 (0%) | 0% | 655 | 655,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 650.00 per share. | 16 Nov 2021 | 4,000 | 32,858 (0%) | 0% | 650 | 2,600,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 650.00 per share. | 16 Nov 2021 | 2,000 | 40,858 (0%) | 0% | 650 | 1,300,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 658.79 per share. | 16 Nov 2021 | 2,000 | 38,858 (0%) | 0% | 658.8 | 1,317,580 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 660.00 per share. | 16 Nov 2021 | 2,000 | 36,858 (0%) | 0% | 660 | 1,320,000 | Common Stock |
| Regeneron Pharma | George L. Sing | Director | Sale of securities on an exchange or to another person at price $ 650.00 per share. | 16 Nov 2021 | 750 | 1,000 (0%) | 0% | 650 | 487,500 | Common Stock |